Related references
Note: Only part of the references are listed.Integrating BRAF/MEK inhibitors into combination therapy for melanoma
K. S. M. Smalley et al.
BRITISH JOURNAL OF CANCER (2009)
Brief Report: Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449.
Charles M. Rudin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
MEK1 mutations confer resistance to MEK and B-RAF inhibition
Caroline M. Emery et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway
Christine A. Pratilas et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Smoothened Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma
Robert L. Yauch et al.
SCIENCE (2009)
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma
Clara Montagut et al.
CANCER RESEARCH (2008)
The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel
Nikolas K. Haass et al.
CLINICAL CANCER RESEARCH (2008)
BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells
Elisa Sala et al.
MOLECULAR CANCER RESEARCH (2008)
Oncogenic BRAFV600E inhibits BIM expression to promote melanoma cell survival
Robert A. Cartlidge et al.
PIGMENT CELL & MELANOMA RESEARCH (2008)
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
James Tsai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway
S. Bauer et al.
ONCOGENE (2007)
Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels
K. S. M. Smalley et al.
BRITISH JOURNAL OF CANCER (2007)
An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells
Keiran S. M. Smalley et al.
CANCER RESEARCH (2007)
Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited
Vanessa C. Gray-Schopfer et al.
CANCER RESEARCH (2007)
Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885
Alastair J. King et al.
CANCER RESEARCH (2006)
Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases
KSM Smalley et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Growth factors rescue cutaneous melanoma cells from apoptosis induced by knockdown of mutated (V600E) B-RAF
C Christensen et al.
ONCOGENE (2005)
Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling
KV Bhatt et al.
ONCOGENE (2005)
Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion
KSM Smalley et al.
AMERICAN JOURNAL OF PATHOLOGY (2005)
A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040
YL Wang et al.
NEOPLASIA (2005)
Mutant V599EB-RAF regulates growth and vascular development of malignant melanoma tumors
A Sharma et al.
CANCER RESEARCH (2005)
B-RAF is a therapeutic target in melanoma
M Karasarides et al.
ONCOGENE (2004)
The RAF proteins take centre stage
C Wellbrock et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?
KSM Smalley
INTERNATIONAL JOURNAL OF CANCER (2003)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Share Paper
